TABLE 2.
Baseline age, sex, migraine data, and treatment outcomes for 3 months follow-up for migraine patients with simple or complex aura and without aura.
| Data | Migraine with aura (n = 45) | Migraine without aura (n = 123) |
P (with vs. without aura) |
P (simple vs. complex aura) |
||
| Overall (n = 45) |
Simple (n = 41) |
Complex (n = 4) |
||||
| Baseline data | ||||||
| Median age, years (IQR) | 38.0 (30–49) |
34 (29.5–49) |
42 (38.3–48) |
45.0 (36–55) |
0.024* | 0.43 |
| Female sex, n (%) | 39 (86.7) | 35 (85.4) | 4 (100) | 102 (82.9) | 0.73 | NA |
| Comorbidity presence, n (%) | 24 (53.3) | 21 (51.2) | 3 (75) | 68 (55.3) | 0.96 | 0.61 |
| Median history of migraine headache, years (IQR) | 5.0 (2–10) |
5 (2–10) |
10 (4–17.5) |
7.0 (2–12) |
0.19 | 0.27 |
| Chronic migraine subtype, n (%) | 16 (35.6) | 14 (34.1) | 2 (50) | 49 (39.8) | 0.61 | 0.61 |
| Chronic migraine with MOH group | 5 (11.1) | 4 (9.8) | 1 (25) | 12 (9.8) | 0.80 | 0.39 |
| Median MMDs/MHDs (IQR) | 12.0 (8–28) |
12 (8–28) |
28 (16–28) |
16.0 (8–28) |
0.73 | 0.11 |
| Mean MMDs/MHDs | 16.6 (9.0) | 15.9 (8.9) | 24 (8) | 16.9 (9.2) | 0.84 | 0.09 |
| Median Thai-version MSQ v. 2.1 score (IQR) | 58.6 (47.2–70.0) |
61.5 (47.2–77.2) |
51.5 (45–57.9) |
62.9 (49.3–80.0) |
0.48 | 0.32 |
| Median Thai-version MIDAS score (IQR) | 5 (5–10) |
5 (0–10) |
3 (0–11.3) |
1 (0–6) |
0.12 | 0.73 |
| Number of preventive medications, n (%) ∙ Monotherapy ∙ Polytherapy |
37 (82.2) 8 (17.8) |
34 (82.9) 7 (17.1) |
3 (75) 1 (25) |
95 (77.2) 28 (22.8) |
0.18 |
0.56 |
| Migraine prevention inhibiting spreading depolarizations used, n (%) | 18 (40) | 18 (43.9) | 0 (0) | 47 (38.2) | 0.97 | NA |
| Treatment outcomes | ||||||
| At 3 months (n) | 45 | 41 | 4 | 123 | ||
| Median MMDs/MHDs (IQR) | 5.0 (3.0–12.0) |
5 (3–12) |
7.5 (2–15.3) |
6.0 (2.0–12.0) |
0.73 | 0.86 |
| Mean MMDs/MHDs (SD) | 8.4 (7.4) | 8.4 (7.5) | 8.3 (6.9) | 9.1 (8.7) | 0.61 | 0.98 |
| Mean reduction from baseline of MMDs/MHDs (SD) | 8.3 (10.3) | 7.6 (10.2) | 15.8 (8.8) | 7.9 (8.9) | 0.79 | 0.13 |
| 30% reduction from baseline of MMDs/MHDs | 32 (71.1) | 28 (68.3) | 4 (100) | 81 (65.9) | 0.65 | NA |
| 50% reduction from baseline of MMDs/MHDs | 27 (60.0) | 24 (58.5) | 3 (75) | 71 (57.7) | 0.93 | 0.64 |
| Median Thai-version MSQ v. 2.1 score (IQR) | 72.1 (61.6–89.7) |
74.4 (63.3–89.7) |
61.5 (49–92.2) |
81.5 (64.4–92.9) |
0.16 | 0.51 |
| Mean improvement from baseline of Thai-version MSQ v. 2.1 (SD) | 15.4 (19.3) | 15.3 (18.9) | 16.1 (26) | 14.3 (21.3) | 0.80 | 0.94 |
| Median Thai-version MIDAS score (IQR) | 0 (0–4.0) |
0 (0–4) |
1.5 (1–7.3) |
4.2 (0–3.0) |
0.92 | 0.22 |
| Mean reduction from baseline of Thai-version MIDAS score (SD) | 3.5 (6.7) | 3.8 (6.5) | 1.5 (9.0) | 1.0 (16.5) | 0.41 | 0.54 |
| Treatment outcomes | ||||||
| At 6 months (n) | 28 | 24 | 4 | 89 | ||
| Median MMDs/MHDs (IQR) | 3.0 (2.0–10.0) |
3 (2–10) |
2.5 (2–21.8) |
5.0 (2.5–10.0) |
0.25 | 0.78 |
| Mean MMDs/MHDs (SD) | 7.1 (7.9) | 6.9 (7.2) | 8.8 (12.8) | 7.3 (7.4) | 0.91 | 0.67 |
| Mean reduction from baseline of MMDs/MHDs (SD) | 8.8 (9.6) | 7.7 (8.9) | 15.3 (12.5) | 8.2 (8.2) | 0.75 | 0.15 |
| 30% reduction from baseline of MMDs/MHDs | 22 (78.6) | 19 (79.2) | 3 (75) | 62 (69.7) | 0.50 | >0.99 |
| 50% reduction from baseline of MMDs/MHDs | 18 (64.3) | 15 (62.5) | 3 (75) | 52 (58.4) | 0.74 | 0.55 |
| Median Thai-version MSQ v. 2.1 score (IQR) | 81.5 (54.3–94.4) |
82.2 (53.3–93) |
57.2 (54.3–57.5) |
80.0 (65.8–91.9) |
0.80 | >0.99 |
| Mean improvement from baseline of Thai-version MSQ v. 2.1 (SD) | 16.3 (21.3) | 15.7 (20.8) | 20.5 (29.3) | 12.8 (21.5) | 0.49 | 0.73 |
| Median Thai-version MIDAS score (IQR) | 4.0 (0–13.3) |
3 (0–14) |
7 (0–7) |
0 (0–4.0) |
0.16 | 0.93 |
| Mean reduction from baseline of Thai-version MIDAS score (SD) | 1.0 (10.6) | 0.9 (10.9) | 1.3 (10.4) | 1.6 (9.8) | 0.81 | 0.96 |
| Treatment outcomes | ||||||
| At most recent follow-up median duration, years (IQR) |
0.8 (0.3–2.8) |
0.5 (0.25–2.5) |
3 (1.9–4.5) |
1.0 (0.5–3.0) |
0.98 | 0.037* |
| Median MMDs/MHDs (IQR) | 4.0 (2.0–9.8) |
4 (2–9.8) |
4 (1.3–16.5) |
4.0 (1.0–8.3) |
0.99 | 0.86 |
| Mean MMDs/MHDs (SD) | 6.2 (6.7) | 6.1 (6.6) | 7.3 (8.8) | 6.9 (8.2) | 0.60 | 0.75 |
| Mean reduction from baseline of MMDs/MHDs (SD) | 10.5 (9.1) | 9.9 (9.0) | 16.8 (9.2) | 9.9 (8.8) | 0.70 | 0.16 |
| 30% reduction from baseline of MMDs/MHDs | 36 (81.8) | 33 (82.5) | 3 (75) | 93 (76.2) | 0.58 | 0.56 |
| 50% reduction from baseline of MMDs/MHDs | 32 (72.7) | 29 (72.5) | 3 (75) | 84 68.9) | 0.77 | >0.99 |
| Median Thai-version MSQ v. 2.1 score (IQR) | 82.9 (60.4–98.7) |
83 (52.6–99) |
80.1 (65.1–94) |
85.8 (71.5–97.2) |
>0.99 | >0.99 |
| Mean improvement from baseline of Thai-version MSQ v. 2.1 (SD) | 19.3 (24.7) | 18.3 (25.5) | 28.2 (15.8) | 18.4 (21.9) | 0.83 | 0.45 |
| Median Thai-version MIDAS score (IQR) | 0 (0–2.5) |
0 (0–3) |
0 (0–0.75) |
0 (0–2.0) |
0.49 | 0.69 |
| Mean reduction from baseline of Thai-version MIDAS score (SD) | 4.8 (12.6) | 4.9 (13.2) | 4.5 (5.7) | 3.1 (11.9) | 0.46 | 0.96 |
MIDAS, migraine disability assessment questionnaire; MMDs/MHDs, monthly migraine/headache days; MOH, medication-overuse headache; MSQ, migraine-specific quality of life questionnaire.